Introduction
The location of the primary tumor has an impact on clinical behavior and has prognostic value in metastatic colorectal cancer (mCRC). Patients with mCRC who harbor right-sided tumors have been shown to have poorer outcomes than those who harbor left-sided tumors. This phenomenon may derive in part from higher frequency of BRAF mutations, increased microsatellite instability and CpG island methylator phenotype, or higher incidences of mucinous differentiation and serrated pathway signature, which are more common in mCRC with right-sided primary tumors (1, 2) . In contrast, amplification of EGFR and ERBB2, chromosomal instability, and TP53 gene mutations are more frequent in left-sided tumors (3). According to a sub-analysis of the CALGB80405 trial, primary tumor sidedness has been identified to be an independent prognostic marker in mCRC (4).
The molecular differences associated with sidedness in mCRC contribute in part to differences in the response to systemic treatment. Retrospective analyses of 2 first-line studies comparing chemotherapy plus cetuximab with chemotherapy plus bevacizumab reported better overall survival (OS) in the chemotherapy plus cetuximab group in patients with left-sided tumors. In contrast, patients with right-sided tumors appeared to receive more benefit from chemotherapy plus bevacizumab (5) . Moreover, a recent meta-analysis suggested that tumor sidedness is a predictive marker of the response to anti-EGFR therapy in patients with RAS wild-type mCRC. Patients with left-sided tumors were shown to derive a greater benefit from chemotherapy plus anti-EGFR than from chemotherapy plus bevacizumab, while right-sided tumors were associated with trends toward detrimental effects of anti-EGFR therapy (6) . On the basis of these results, the National Comprehensive Cancer Network (NCCN) guideline has recommended to consider the primary tumor site when deciding the first-line treatment for mCRC (7) . Actually, anti-EGFR therapy with cetuximab or panitumumab is recommended for only RAS wild-type and left-sided tumors. In addition, the pan-Asian adapted ESMO consensus guidelines have proposed that tumor sidedness matters when we treat patients with RAS/BRAF wild-type tumors (8) .
Although increasing evidence suggests that tumor sidedness is a predictor of the response to anti-EGFR antibodies, this does not mean that all patients with right-sided tumors should clinically avoid receiving anti-EGFR antibodies as an initial treatment. Data from prospective clinical trials have demonstrated that a few patients with right-sided tumors had a good depth of response and that even though a durable response was achieved in a larger proportion of patients with left-sided tumors than in patients with right-sided tumors, a few patients with right-sided tumors also had rapid and deep responses (9) . Some patients with right-sided tumors may be responders who benefit from anti-EGFR antibodies and should receive anti-EGFR-based chemotherapy as an initial treatment. Therefore, there may be biomarkers to elucidate the subset of mCRC patients who are likely to benefit from anti-EGFR treatment in each side.
We therefore performed a biomarker study to establish responders to anti-EGFR treatment using tissue samples obtained from patients enrolled in prospective clinical trials.
The aim of this study was to investigate which genes are associated with the response to cetuximab treatment depending on tumor sidedness in patients with mCRC who received first-line cetuximab treatment. We retrospectively collected tissue samples from 2 prospective clinical trials which evaluated combination therapy with cetuximab and oxaliplatin-based chemotherapy as first-line treatment, the modified-FOLFOX6 regimen (JACCRO CC-05: N=57, UMIN000004197) (10) and the SOX regimen (JACCRO CC-06: N=67, UMIN000007022) (11) for mCRC patients with KRAS wild-type tumors (Supplementary Figure 1) . This biomarker study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical committee of each participating institute. Written informed consent was obtained from the patients before enrollment. If the investigators could not obtain informed consent, the patient was eligible for enrollment under permission by the institutional review board of each institute. Tissue samples at the time of biopsy or surgery before chemotherapy were collected.
Materials and Methods

Study design and patient population
Assessment of efficacy
The endpoints of this biomarker study were progression-free survival (PFS) and OS.
The JACCRO trials included the same secondary endpoints of OS and PFS based on disease progression detected by external review or death from any cause. Disease progression was evaluated according to RECIST, version 1.1 by the investigators and was then validated by an external review board. 
RNA isolation and gene expression analysis
Statistical evaluation
The R statistical software (version 3. classes of genes associated with outcomes in each side by the GSEA Preranked analysis based on the hazard ratio of each gene calculated during the univariate Cox regression analysis. The biological process entries in Gene Ontology terms (category c5.bp) was used for the target gene sets for GSEA. The gene sets satisfying both P < 0.05 and false discovery rate (FDR) < 0.25 were considered statistically significant. SAS 9.0.3 software (SAS Institute, Cary, NC, USA) was used to perform all analyses unless specified otherwise. All tests were 2-sided with a significance level of 0.05.
Results
Patient characteristics
A total of 77 patients were studied. Sixty-three (82%) of the patients had left-sided tumors, and 13 (17%) had right-sided tumors. The patient characteristics are summarized in Supplementary Table 1 . There were no statistically significant differences in characteristics between patients with left-sided tumors and those with right-sided tumors. In the enrolled patients, the ORR was 73%. The median PFS and OS were 10.0 months (95% CI 8.8-11.8 months) and 33.9 months (95% CI 26.5-not reached), respectively. Univariate Cox regression analysis included 69 patient samples that passed the internal Quality Control metrics of HTG EdgeSeq Oncology Biomarker Panel.
Identified significant genes in both sides
Overexpression of BECN1 (log2(CPM) ≥ 6. In the right-sided tumor group (n=9), the Cox regression analysis showed that 44 genes were associated with clinical outcomes for PFS, and 33 genes were associated with clinical outcomes for OS (P<0.01). Eleven of the 44 genes associated with PFS and 2 of the 33 genes associated with OS were associated with favorable survival. Moreover, the analysis identified 4 genes (CST6, FGF18, SHC3, and TMEM57) that were associated with both worse PFS and worse OS. There was no gene significantly associated with both better PFS and OS.
GSEA identified significant pathways associated with outcomes of tumors on each side
In the GSEA, we identified gene sets of left-sided tumors and right-sided tumors that 
were associated with PFS or OS and had P-values of less than 5% and false discovery rates of less than 25% ( Table 1 and Table 2 ).
In the left-sided tumor group, one gene set regarding regulation of DNA replication was significantly associated with better OS. Sixteen gene sets correlated with better PFS, while 4 gene sets were associated with worse PFS. Among 16 gene sets, 3 gene sets related to angiogenesis, extracellular structure, or chromatin organization were strongly associated with favorable PFS (FDR<0.05).
In the right-sided tumor group, 13 gene sets correlated with better PFS. Ten gene sets were associated with better OS, while 10 other gene sets correlated with worse OS. In particular, gene sets of organonitrogen compound biosynthetic process and translational initiation were strongly associated with favorable PFS. Subcellular component and leukocyte migration genes correlated with better OS, whereas gene sets of DNA metabolic process, DNA repair, and cellular response to DNA damage stimulus were strongly associated with worse OS (FDR<0.05) (Figure 4 ).
Discussion
Our study demonstrated that there were significant differences in gene expression levels which were associated with clinical outcomes between primary tumor sidedness in mCRC patients treated with first-line cetuximab-based chemotherapy. A pooled analysis of 6 randomized trials evaluating the prognostic and predictive values of primary tumor sidedness in patients with RAS wild-type mCRC confirmed that adding an anti-EGFR drug had a greater effect than adding bevacizumab; this effect was greatest in patients with left-sided tumors (6).
However, it has been reported that some patients with right-sided tumors respond to chemotherapy combined with anti-EGFR antibody (9, 13) . In present study, we found 16 genes in the left-sided tumor group and 44 significant genes in the right-sided tumor group that were significantly associated with PFS. There were no common genes that were significantly associated with PFS in both tumor side groups. Moreover, in the GSEA, gene sets associated with PFS differed between the left-sided and right-sided tumor groups. This finding suggests that gene expression signatures may explain differences in cetuximab efficacy dependent on tumor sidedness.
Patients with left-sided tumors are more likely to respond to anti-EGFR antibodies, leading to survival benefit. However, some patients do not respond to anti-EGFR therapy even if they have left-sided primary tumors, indicating that RAS and sidedness may be not a sufficient predictor of the response to anti-EGFR antibodies. There is an urgent need for predictive biomarkers for anti-EGFR therapy to identify certain responders among mCRC patients with left-sided primary tumors. Our findings suggest that NOTCH1 gene expression is significantly associated with survival in the left-sided tumor group, but not in the right-sided group. A family of membrane-bound receptors related to the NOTCH proteins (NOTCH1, NOTCH2, NOTCH3, and NOTCH4) contribute to regulating tumor cell proliferation, differentiation, apoptosis, and migration (14, 15) . Several biomarker studies have reported that increased NOTCH1 expression is associated with lymph node metastasis in CRC (16).
Moreover, NOTCH1 high-expression had multivariable associations with poor outcomes in CRC (16-19). NOTCH1 mediates the resistant effects of regorafenib in colorectal cancer cells (20) . It has also been shown that NOTCH1 expression is a detrimental prognostic factor in mCRC patients who receive chemotherapy plus the anti-VEGF antibody bevacizumab (21). 
ALDH1A1 expression was not related to differences in survival time (27); however, it has been shown that nuclear expression of ALDH1A1 is significantly associated with shorter OS and that the ratio of the ALDH1A1 level in adjacent mucosa to that in tumor tissue is closely related to invasion, metastasis, and prognosis in CRC (25, 28) . A previous molecular subtyping study demonstrated that a subtype that is stem-like and includes upregulation of genes involved in matrix remodeling and epithelial-mesenchymal transition carries a very poor prognosis and, moreover, is refractory to EGFR-targeted therapy (29) . Therefore, the ALDH1A1 gene may be a prognostic factor but may be also a predictor of a poor response to cetuximab in mCRC.
In the right-sided tumor group, the CST6, FGF18, SHC3, and TMEM57 genes were associated with worse PFS and OS. Cystatin 6 (CST6) has been considered to be a tumor-suppressor in breast tissue (30) , reducing breast cancer cell proliferation, adhesion to endothelial cells, matrigel invasion, and migration (31) , but this has not been reported in CRC.
Loss of CST6 gene expression has ascribed promoting hypermethylation in breast cancer (30) . Cystatin M, a protein coded by the CST6 gene, which controls the activity of legumain, is found to be a oncogene and an indicator of a poor prognosis in colorectal and breast cancers, but also to be overexpressed in the majority of human solid tumors (32). Fibroblast growth factor receptor 3 (FGFR3) has been reported to negatively regulate bone growth (33) and also to be involved in carcinogenesis. Up-regulation of fibroblast growth factor 18 (FGF18), one of ligands of FGFR3, was shown to have oncogenic impact (34) The BECN1 high-expression was found to be significantly associated with favorable survival in both tumor sidedness groups of our study. BECN1 has an important role in canonical autophagy, to regulate autophagic phosphatidylinositol 3-phosphate generation and recruit additional ATG proteins for autophagosome formation (37) . Autophagy-related genes are over-regulated or down-regulated in cancers, but also significantly correlate with poor prognoses, suggesting the complex biological role of autophagy in cancer (38, 39) .
Monoallelic loss of the BECN1 gene causes susceptibility to metabolic stress and promotes tumorigenesis (40) . A retrospective review from clinicopathological and immunohistochemical data indicated that the absence of autophagy-related protein expression correlated with poor prognosis in CRC; therefore, suggested that these proteins may be novel prognostic markers (41). Our results suggest that BECN1 may be a promising gene for predicting favorable outcomes in mCRC.
Our study had several limitations that must be taken into account when interpreting the results. A major limitation was that our study population may include patients with non-exon 2 KRAS and NRAS mutations. An extended RAS test is now recommended for patient selection for anti-EGFR therapy as it is known that patients with non-exon 2 KRAS and NRAS mutations do not derive benefit from anti-EGFR antibodies (42,43). These patients should be excluded from the analysis; however, it was not able to check RAS status due to lack of the remaining tissues samples. The sample size of patients with right-sided primary tumors (n=13) was very small in this study; therefore, it may be not statistically reliable. It is difficult to exactly assess the impact of candidate genes on the effectiveness of cetuximab since the patient cohort comprised only patients who received cetuximab, meaning that we are unable to evaluate the genes as predictive markers. We found that there were no common genes and pathways that were significantly associated with PFS in both the left-sided and right-sided tumor groups; however, this may have resulted from the small study group. To resolve these limitations, our findings will be validated using data of an on-going randomized trial, the DEEPER (NCT02515734), which evaluates triplet-regimen plus cetuximab or bevacizumab as first-line treatment for RAS wild-type mCRC.
In conclusion, our data suggest that genes contributing to the response or resistance to cetuximab treatment may differ between right-sided tumors and left-sided tumors in patients with mCRC. NOTCH1 may potentially discriminate certain responders to cetuximab in patients with left-sided primary tumors, while several genes may contribute resistance to cetuximab in patients with right-sided primary tumors. These findings need to be confirmed in studies using larger cohorts with RAS wild-type mCRC patients. 
